NCT07666217Active, not recruiting
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
Comparison of Perioperative and Postoperative Outcomes of Single-port (SP) Extraperitoneal Approach and Multi-port (MP) Transperitoneal Approach in Robot-assisted Radical Prostatectomy：A Propensity Score-matched Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This multicenter retrospective observational study aims to compare perioperative and postoperative outcomes between the da Vinci SP extraperitoneal approach (SP-EA) and the robotic multi-port transperitoneal approach (MP-TA) in robot-assisted radical prostatectomy for localized prostate cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 625 (estimated)
- First submitted
- 3 Jun 2026
- Start date
- 26 Mar 2026
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Intuitive Surgical
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT07666217
What you commit to
- Study type: Observational
- Planned participants: 625
- From 26 Mar 2026 to the primary completion date, 30 Sept 2026
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who underwent RARP using surgical approaches other than those specified in the inclusion criteria (e.g., transvesical approach)
Other illness
- Patients with a history of radiotherapy for prostate cancer
Other
- Patients who have expressed an intention to refuse the use of their data for this study
- Patients who underwent RARP with pelvic lymph node dissection (PLND)
- Any other patients whom the principal investigator or a co-investigator deem inappropriate, such as those with missing outcome data.
Who the study is looking for
- Patients with localized prostate cancer (clinical stage T1-T3a, N0, M0) eligible for radical prostatectomy
- Patients who underwent RARP via SP-EA or MP-TA on or after January 1, 2023
- Patients with available postoperative follow-up data for ≥6 months (≥166 days) \*note 1)
Sex: Male · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ageo Central General Hospital Coordinator of this site? Confirm its status | Ageo | Japan | Unknown status |
| Ichinomiyanishi Hospital Coordinator of this site? Confirm its status | Ichinomiya | Japan | Unknown status |
| Kyoto City Hospital Coordinator of this site? Confirm its status | Kyoto | Japan | Unknown status |
| Tokyo Medical Center Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| National Cancer Center Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| Fujita Health University Hospital Coordinator of this site? Confirm its status | Toyoake | Japan | Unknown status |
| Mie University Hospital Coordinator of this site? Confirm its status | Tsu | Japan | Unknown status |
| Saiseikai Yokohamashi Tobu Hospital Coordinator of this site? Confirm its status | Yokohama | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.